



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Joe Manchin III
Governor

Martha Yeager Walker
Secretary

West Virginia Department of Health and Human Resources
Bureau for Medical Services
Pharmaceutical and Therapeutics (P & T) Committee
February 7, 2007 – 9:00 a.m.
Charleston Civic Center
WV Room 105
Charleston, West Virginia

MINUTES

Members Present:

David Avery, M.D.
John D. Justice, M.D.
Steven R. Matulis, M.D.
Barbara Koster, MSN, RNC-ANP
Michael Grome, PA-C (telephone)
Scott Brown, R.Ph.
Rodney Fink, D.O.
Teresa Frazer, M.D., FAAP
Ahmed Faheem, M.D.
Jeffrey Ashley, M.D.
James Bartsch, R.Ph.
Teresa Dunsworth, PharmD (telephone)
Harriet Nottingham, R. Ph.
Gretchen Oley, M.D.

Members Not Present

None

DHHR/BMS Staff Present

Nora Antlake, Counsel
Peggy King, Pharmacy Director
Gail Goodnight, Rebate Coordinator
Vicki Cunningham, DUR Coordinator
Lynda Edwards, Secretary

Contract Staff/Provider Synergies Present:

Steve Liles, PharmD

Other Contract Staff/State Staff Present:

Stephen Small, RDTP
Eric Sears, Unisys

I. Call to Order

Dr. Steven Matulis, Chairperson, called the meeting to order at 9:10 a.m.

II. Housekeeping

Peggy King, R.Ph., Pharmacy Director, was recognized, and she advised the audience on how the meeting would be conducted.

All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

III. Approval of Minutes of August 16, 2006 Meeting

Chairman Matulis asked for approval of the minutes from the last meeting. A motion was made and seconded, votes were taken and the motion carried to approve the minutes as submitted.

IV. Public Comment Period

Ms. King explained that the public comment period would be a 60-minute session. She explained the speaker sign-up process. The sign-up begins at 8:00 a.m. and each speaker will be limited to three minutes.

She also stated that the session is not interactive and that no slide presentations or handouts would be distributed during the meeting. She informed the audience that materials they wanted submitted to the Committee had to be delivered to Lynda Edwards after the comment period, and she would distribute them to the Committee. She stated that only two page materials will be mailed to the Committee members and other materials should be brought to the meeting for distribution. The following individuals took the floor:

Iyer Ramakrishnan, Abbott: Dr. Ramakrishnan talked about Tricor and gemfibrozil. He stated that he would like the Committee to keep them on the Preferred Drug List.

Pyar Noorani, WVU: Dr. Noorani discussed anti-epileptic drugs and that children have a limited number of drugs available to them and should have access to all the medications.

Timothy Birner, M.D., Sanofi Aventis: Dr. Birner spoke about Lovenox and its being FDA approved for renal patients. He said he would like the Committee to keep it on the Preferred Drug List.

Majid Tabesh, Sanofi Aventis: Dr. Tabesh talked about Uroxatrol. He said that the medication is efficacious and safe. He asked that the Committee consider keeping Uroxatrol on the formulary.

Keith David, Sanofi Aventis: He spoke about Ambien CR. He stated that Ambien CR is safe and effective for long-term use. He asked that the Committee consider putting Ambien CR on the Preferred Drug List.

Kelly Hollenack, Takeda: Dr. Hollenack spoke about Rosarem. She said that Rosarem increases total sleep time. She stated that abuse studies showed that Rosarem has no street value or abuse potential.

Leonard Bennett, Jr., GSK: Dr. Bennett spoke about Type II diabetes. He said that patients with insulin resistance have shown significant improvement when treated with Avandia. He asked that Avandia and Avandamet be kept on the Preferred Drug List.

Richard Bowman, Sepracor: Dr. Bowman spoke about Lunesta. He said tolerance does not develop in patients who use this medication for up to 12 months.

Michelle Endicott, Dermik: Dr. Endicott discussed acne preparations. She explained that acne scarring is preventable if treated appropriately. She said Benzaclin helps to keep patients from becoming antibiotic resistant.

Hussein El-Khatib, M.D., Thomas Hospital: Dr. Khatib, psychiatrist, spoke about mental illness. He said that someone dies every sixteen minutes by suicide. He stated that duloxetine works well for patients with pain as well as fibromyalgia. He also spoke about Ambien CR because it has less potential for abuse given it does not have immediate release.

Amy Kemner, Eli Lilly: Ms. Kemner discussed Cymbalta. She explained that pain is a common symptom of depressed patients. She said that Cymbalta achieves a high remission rate and is used in pain caused by diabetic neuropathy.

Kent Hunter, Pfizer: Mr. Hunter spoke about Lyrica. He stated that Lyrica gives rapid pain relief and little potential for drug reactions. He discussed triptans and updated information.

Holly Lissila, Pfizer: Dr. Lissila discussed Lipitor. She said that she would like for the Committee to put Lipitor on the formulary. She stated that Lipitor is the only statin shown to reduce the risk of stroke.

Jeff Hurd, GSK: Dr. Hurd spoke on Lamictal. He said that it was very effective in epilepsy. He stated that it has indications for children age two and older. He stated that it does have a positive outcome in bi-polar treatment.

Robert Pannone, Amgen: Mr. Pannone spoke about Aranesp. He stated that dialysis patients with anemia were much improved with Aranesp.

Richard Peterson, Santarus: Dr. Peterson discussed the benefits of proton pump inhibitors and Zegerid. He stated that in a head-to-head study with Nexium, Zegerid and Prevacid, that Zegerid was the superior proton pump inhibitor. He requested that the Committee add Zegerid to the Preferred Drug List.

Pinakin Attawala, Schering-Plough: Dr. Attawala spoke about Zetia, and Vytorin. He stated that side effects of most statins are dose related.

Robert Fissel, Schering-Plough: Mr. Fissel commented on PegIntron. He discussed the effectiveness of PegIntron in trials. He commented that he would like for the Committee to keep PegIntron on the formulary.

Mark Borrelli, Novo Nordisk: Mr. Borrelli spoke about Norditropin. He said that Norditropin is indicated for both pediatric and adult patients with growth hormone deficiency. He said that there is dosing flexibility with the 5, and 10 mg. pens.

Mark Veerman, Ortho-McNeil Janssen: Mr. Veerman, R.Ph. spoke about Axert. He stated that two studies have shown that Axert has attributes valued by patients and physicians in providing sustained pain freedom, and rapid onset of pain relief. He requested that Axert remain on the formulary.

Julian Espiritu, Genzyme: Dr. Espiritu spoke about sevelamer. He said that it decreased hospitalization and mortality rate. He said that it is a preferred agent for patients with cardiovascular calcification. He requested that sevelamer remain on the formulary.

Natalia Kujdych, Serona: Ms. Kujdych spoke on Rebif. She said that patients that were treated earlier had better outcomes than those that were treated later.

Dr. Matulis advised the audience that the public comment section had ended. A motion was made to move to the Executive Session. The motion was seconded and carried. The Committee adjourned to Executive Session at 10:30 p.m. Dr. Matulis stated that another Executive Session/Lunch will be from 1:00 p.m. to 2:00 p.m.

V. Old Business

No old business was discussed.

VI. New Business

No new business was discussed.

VII. Therapeutic Category Reviews

There were 27 categories of drugs scheduled for review. Steve Liles gave an overview at the beginning of each category. The Committee reviewed and discussed each category and made the following recommendations:

1. Acne Agents, Topical

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies with the addition of adding Benzaclin and Duac. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ACNE AGENTS, TOPICAL	ANTIBIOTICS	
	AKNE-MYCIN (erythromycin) Clindamycin erythromycin	CLINDAGEL (clindamycin) EVOCLIN (clindamycin)
	RETINOIDS	
	RETIN-A MICRO (tretinoin) TAZORAC (tazarotene) tretinoin	DIFFERIN (adapalene)
	OTHERS	
AZELEX (azelaic acid) BENZAACLIN (benzoyl peroxide/clindamycin) benzoyl peroxide CLINAC BPO (benzoyl peroxide) DUAC (benzoyl peroxide/ clindamycin)	BENZAMYCIN PAK (benzoyl peroxide/erythromycin) BENZIQU (benzoyl peroxide) BREVOXYL (benzoyl peroxide) erythromycin/benzoyl peroxide INOVA (benzoyl peroxide) INOVA 4/1 (benzoyl peroxide/ salicylic acid) KLARON (sodium sulfacetamide) NEOBENZ MICRO (benzoyl peroxide) NUOX (benzoyl peroxide/sulfur) SULFOXYL (benzoyl peroxide/sulfur) TRIAZ (benzoyl peroxide) ZACLIR (benzoyl peroxide) ZODERM (benzoyl peroxide)	

2. Otic Fluoroquinilones

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
OTIC FLUOROQUINILONES	CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin) neomycin/polymyxin/hydrocortisone	CIPRO HC (ciprofloxacin/hydrocortisone)

3. Antihistamines, Minimally Sedating

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANTIHISTAMINES, MINIMALLY SEDATING	ANTIHISTAMINES	
	ALAVERT (loratadine) CLARINEX Syrup (desloratadine) loratadine TAVIST-ND (loratadine)	ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARITIN (loratadine) fexofenadine ZYRTEC (cetirizine)
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS	
	ALAVERT-D (loratadine/pseudoephedrine) loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/pseudoephedrine) CLARINEX-D (desloratadine/pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) ZYRTEC-D (cetirizine/pseudoephedrine)

4. Hepatitis C Agents

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
HEPATITIS C TREATMENTS^{CL}	PEGASYS (pegylated interferon) ribavirin	COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) REBETOL (ribavirin)

CL-Clinical PA

5. Ulcerative Colitis Agents

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies with the addition of Pentasa. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ULCERATIVE COLITIS AGENTS	ORAL	
	ASACOL (mesalamine) DIPENTUM (olsalazine) PENTASA (mesalamine) sulfasalazine	AZULFIDINE (sulfasalazine) COLAZAL (balsalazide)
	RECTAL	
	CANASA (mesalamine) mesalamine	ROWASA (mesalamine)

6. Proton Pump Inhibitors

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies with the addition of Prevacid Solutab. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
PROTON PUMP INHIBITORS (Oral)	NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole) PREVACID Solu-Tabs (lansoprazole)	ACIPHEX (rabeprazole) omeprazole PREVACID Suspension (lansoprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate)

7. BPH Treatments

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
BPH AGENTS	ALPHA BLOCKERS	
	doxazosin FLOMAX (tamsulosin) trazosin UROXATRAL (alfuzosin)	CARDURA (doxazosin) CARDURA XL(doxazosin) HYTRIN (terazosin)
	5-ALPHA-REDUCTASE (5AR) INHIBITORS	
	AVODART (dutasteride)	finasteride PROSCAR (finasteride)

8. Bladder Relaxant Preparations

Steve Liles recommended the following drugs for the Preferred Drug List. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
BLADDER RELAXANT PREPARATIONS	DITROPAN XL (oxybutynin) ENABLEX (darifenacin) oxybutynin OXYTROL (oxybutynin) SANCTURA (trospium) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin)

9. Phosphate Binders

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
PHOSPHATE BINDERS	FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)	

10. Erythropoiesis Stimulating Proteins

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ERYTHROPOIESIS STIMULATING PROTEINS^{CL}	ARANESP (darbepoetin) PROCRIT (rHuEPO)	EPOGEN (rHuEPO)

11. Growth Hormone

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
GROWTH HORMONE^{CL}	GENOTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) TEV-TROPIN (somatropin)	HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin) ZORBTIVE (somatropin)

CL-Clinical PA

12. Hypoglycemics, Meglitinides

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
HYPOGLYCEMICS, MEGLITINIDES	STARLIX (nateglinide)	PRANDIN (repaglinide)

13. Hypoglycemics, TZD

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
HYPOGLYCEMICS, TZDS	THIAZOLIDINEDIONES	
	ACTOS (pioglitazone)	
	AVANDIA (rosiglitazone)	
	TZD COMBINATIONS	
	ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin) AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride)	

14. Angiotensin II Receptor Blockers

Steve Liles recommended the following drugs for the Preferred Drug List. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)	ANGIOTENSIN RECEPTOR BLOCKERS	
	AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)	ATACAND (candesartan) TEVETEN (eprosartan)
	ARB/DIURETIC COMBINATIONS	
	AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ)

15. Beta-Blockers

Steve Liles recommended the following drugs for the Preferred Drug List. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
BETA BLOCKERS (Oral)	BETA BLOCKERS	
	acebutolol atenolol betaxolol bisoprolol INDERAL LA (propranolol) metoprolol nadolol pindolol propranolol sotalol timolol TOPROL XL (metoprolol)	BETAPACE (sotalol) BLOCADREN (timolol) CARTROL (carteolol) CORGARD (nadolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) ZEBETA (bisoprolol)
	BETA- AND ALPHA- BLOCKERS	
	COREG (carvedilol) labetalol	COREG CR (carvedilol) ^{NR} TRANDATE (labetalol)

16. Calcium Channel Blockers

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
CALCIUM CHANNEL BLOCKERS (Oral)	SHORT-ACTING	
	diltiazem verapamil	ADALAT (nifedipine) CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)
	LONG-ACTING	
	CARDIZEM LA (diltiazem) diltiazem DYNACIRC CR (isradipine) felodipine nifedipine SULAR (nisoldipine) verapamil VERELAN PM (verapamil)	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD (diltiazem) CARDIZEM SR (diltiazem) COVERA-HS (verapamil) DILACOR XR (diltiazem) ISOPTIN SR (verapamil) NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) TIAZAC (diltiazem) VERELAN (verapamil)

17. ACE Inhibitor/CCB Combinations

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried. A motion was made to break for lunch. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS	LOTREL (benazepril/amlodipine) TARKA (trandolapril/verapamil)	LEXXEL (enalapril/felodipine)

18. Lipotropics, Other

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
LIPOTROPICS, OTHER (non-statins)	BILE ACID SEQUESTRANTS	
	cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevalam)
	CHOLESTEROL ABSORPTION INHIBITORS	
		ZETIA (ezetimibe)
	FATTY ACIDS	
		OMACOR (omega-3-acid ethyl esters)
	FIBRIC ACID DERIVATIVES	
	fenofibrate gemfibrozil TRICOR (fenofibrate)	ANTARA (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)
NIACIN		
niacin NIASPAN (niacin)	NIACELS (niacin) NIADELAY (niacin) SLO-NIACIN (niacin)	

19. Lipotropics, Statins

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies with the addition of Lipitor. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
LIPOTROPICS, STATINS	STATINS	
	ALTOPREV (lovastatin) CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin simvastatin	MEVACOR (lovastatin) PRAVACHOL (pravastatin) pravastatin ZOCOR (simvastatin)
	STATIN COMBINATIONS	
	ADVICOR (lovastatin/niacin) VYTORIN (ezetimibe/simvastatin)	CADUET (atorvastatin/amlodipine)

20. Anticoagulants, Injectable

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANTICOAGULANTS, INJECTABLE	ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin)	INNOHEP (tinzaparin)

21. Multiple Sclerosis Agents

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
MULTIPLE SCLEROSIS AGENTS^{CL}	AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer) REBIF (interferon beta-1a)	

22. Anticonvulsants

Dr. Liles recommended the following drugs for the Preferred Drug List. A motion was made to accept the recommendations of Provider Synergies with the addition of Lyrica. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANTICONVULSANTS	BARBITURATES	
	mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)
	HYDANTOINS	
	PEGANONE (ethotoin) phenytoin	DILANTIN (phenytoin) PHENYTEK (phenytoin)
	SUCCINIMIDES	
	CELONTIN (methsuximide) ethosuximide	ZARONTIN (ethosuximide)
	BENZODIAZEPINES	
clonazepam DIASTAT (diazepam rectal) diazepam	KLONOPIN (clonazepam)	

ADJUVANTS	
Carbamazepine CARBATROL (carbamazepine) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) EQUETRO (carbamazepine) FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) KEPPRA (levetiracetam) LAMICTAL (lamotrigine) LYRICA (pregabalin) TOPAMAX (topiramate) TRILEPTAL (oxcarbazepine) valproic acid zonisamide	DEPAKENE (valproic acid) NEURONTIN (gabapentin) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) ZONEGRAN (zonisamide)

23. Antidepressants, Other

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies with the addition of Cymbalta. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANTIDEPRESSANTS, OTHER (second generation, non-SSRI)	bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone	bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) nefazodone REMERON (mirtazapine) SERZONE (nefazodone) WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)

24. Sedative Hypnotics

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded. An amendment motion was made for the addition of Lunesta. The motion was seconded. Votes were taken on the amendment, and the motion failed. Votes were taken and the motion to accept Provider Synergies recommendation failed. Discussion ensued about generics.

A motion was made to accept temazepam as the only preferred drug. The motion was seconded, votes were taken and the motion passed.

DRUG CLASS	PREFERRED	NON-PREFERRED
SEDATIVE HYPNOTICS	BENZODIAZEPINES	
	temazepam	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) triazolam
	OTHERS	
		AMBIEN (zolpidem) AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon)

25. Antimigraine Agents, Triptans

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies with the addition of Relpax to the preferred drug list. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANTIMIGRAINE AGENTS, TRIPTANS	AMERGE (naratriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) RELPAX (eletriptan)	AXERT (almotriptan) FROVA (frovatriptan) ZOMIG (zolmitriptan)

26. Analgesics, Narcotic Short

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
ANALGESICS, NARCOTIC SHORT (Non-parenteral)	SHORT ACTING	
	APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone propoxyphene/APAP tramadol tramadol/APAP	ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine COMBUNOX (oxycodone/ibuprofen) DARVOCET (propoxyphene/APAP) DARVON (propoxyphene) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LORCET, LORTAB (hydrocodone/APAP) meperidine OPANA (oxymorphone) OXYFAST, OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) propoxyphene TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen)

27. Analgesics, Narcotic Long

Steve Liles recommended the following list be approved. A motion was made to accept the recommendations of Provider Synergies. The motion was seconded, votes were taken and the motion carried.

DRUG CLASS	PREFERRED	NON-PREFERRED
	LONG-ACTING	
	DURAGESIC (fentanyl) KADIAN (morphine) methadone morphine SR	AVINZA (morphine) fentanyl MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) ULTRAM ER (tramadol)

VIII. Next Meeting Date

The next meeting date of the P & T Committee will be **August 22, 2007**.

IX. Other Business

No other business was discussed.

X. Adjournment

A motion was made, was seconded, votes were taken and the motion carried to adjourn the meeting of the Pharmaceutical and Therapeutics Committee.